Targeting MECOM/EVI1 in AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies new ways to target a specific genetic change in acute myeloid leukemia (AML), called MECOM or atypical 3q26 rearrangements. If your leukemia test shows one of these changes, the study may offer a treatment approach aimed at that target.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML (acute myeloid leukemia)
- Your leukemia test shows MECOM or an atypical 3q26 rearrangement
- You must be 18 years or older
- You can sign informed consent to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This Phase 2 trial tests a new combination treatment (the “CAV regimen”) for people with relapsed or refractory acute myeloid leukemia (AML). It may help your body control leukemia again, especially if prior standard intensive treatments were not enough or the leukemia came back.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This trial tests adding a new targeted drug, revumenib, to two standard AML medicines (azacitidine and venetoclax) for adults with a specific gene change (NPM1 mutation or KMT2A rearrangement) who cannot receive strong chemotherapy. The goal is to see if the combination works better.
This trial tests a combination of two experimental drugs, ziftomenib and mezigdomide, for people whose acute myeloid leukemia (AML) has come back or not responded to prior treatment. It's designed for those whose leukemia cells have a specific genetic change (KMT2A rearrangement or NPM1 mutation).
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.